IL-1beta Inhibitors & Biosimilars
2 drugsAbout IL-1beta
Interleukin-1beta (IL-1beta) is a potent pro-inflammatory cytokine that plays a critical role in the body's immune response. As a signaling protein, it mediates inflammation and has become an important drug target.
IL-1beta inhibitors have shown clinical success, underscoring its therapeutic significance in immunology. Currently, there is no genetic evidence data available linking IL-1beta to specific diseases in our dataset.
Two approved drugs target IL-1beta: KINERET (anakinra) and ARCALYST (rilonacept). These drugs are biologics (other) and fusion proteins, developed by BIOVITRUM AB and KINIKSA PHARMACEUTICALS, respectively.
Top IL-1beta Drugs
BIOVITRUM AB and KINIKSA PHARMACEUTICALS are the only two companies with approved IL-1beta drugs.
Low market concentration suggests moderate entry barriers for new companies developing IL-1beta inhibitors.
IL-1beta Drug Modality Landscape
Modalities
Routes of Administration
IL-1beta requires biologic approaches (biologic (other)), likely due to its structure or location.
Small molecule IL-1beta inhibitors represent a whitespace opportunity to expand therapeutic options.
📈 Modality Evolution
other biologics pioneered IL-1beta targeting (2001), with fusion proteins entering more recently (2008).
IL-1beta Clinical Trials 149 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IL-1beta. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 39 | 23 | 10 | 6 | 70% |
| Phase 2 | 77 | 49 | 14 | 13 | 78% |
| Phase 3 | 25 | 13 | 4 | 8 | 76% |
| Phase 4 | 8 | 2 | 5 | 1 | 29% |
Top Sponsors
By Modality
IL-1beta Drug Approval Timeline (2001 - 2008)
The first IL-1beta drug was approved in 2001 (KINERET), and the most recent in 2008 (ARCALYST).
The approval timeline suggests a potential saturation, requiring novel approaches for future drug development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 84 (8 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IL-1beta. A trial counts if an approved drug acting on IL-1beta is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.